Overview

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Status:
Completed

Trial end date:
2014-02-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Methotrexate
Peficitinib